These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26989206)

  • 81. Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphoma.
    Kanate AS; Kharfan-Dabaja MA; Hamadani M
    Bone Marrow Res; 2012; 2012():897215. PubMed ID: 23097707
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas.
    Yi JH
    Blood Res; 2021 Apr; 56(S1):S1-S4. PubMed ID: 33935029
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.
    Wang TP; Scott JH; Barta SK
    Ther Adv Hematol; 2017 Dec; 8(12):329-344. PubMed ID: 29204260
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Investigating the missing heritability of fetal haemoglobin level in Africa.
    Wonkam A
    Br J Haematol; 2020 Dec; 191(5):668-670. PubMed ID: 33094841
    [No Abstract]   [Full Text] [Related]  

  • 85. Splenic marginal zone lymphoma: from genetics to management.
    Arcaini L; Rossi D; Paulli M
    Blood; 2016 Apr; 127(17):2072-81. PubMed ID: 26989207
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Is watch and wait still acceptable for patients with low-grade follicular lymphoma?
    Armitage JO; Longo DL
    Blood; 2016 Jun; 127(23):2804-8. PubMed ID: 26994147
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.
    Fenske TS; Ahn KW; Graff TM; DiGilio A; Bashir Q; Kamble RT; Ayala E; Bacher U; Brammer JE; Cairo M; Chen A; Chen YB; Chhabra S; D'Souza A; Farooq U; Freytes C; Ganguly S; Hertzberg M; Inwards D; Jaglowski S; Kharfan-Dabaja MA; Lazarus HM; Nathan S; Pawarode A; Perales MA; Reddy N; Seo S; Sureda A; Smith SM; Hamadani M
    Br J Haematol; 2016 Jul; 174(2):235-48. PubMed ID: 26989808
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Central nervous system prophylaxis in diffuse large B-cell lymphoma.
    Zahid MF; Khan N; Hashmi SK; Kizilbash SH; Barta SK
    Eur J Haematol; 2016 Aug; 97(2):108-20. PubMed ID: 27096423
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma.
    Roschewski M; Staudt LM; Wilson WH
    Blood; 2016 Jun; 127(25):3127-32. PubMed ID: 27081097
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
    Arber DA; Orazi A; Hasserjian R; Thiele J; Borowitz MJ; Le Beau MM; Bloomfield CD; Cazzola M; Vardiman JW
    Blood; 2016 May; 127(20):2391-405. PubMed ID: 27069254
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Coiffier B; Thieblemont C; de Guibert S; Dupuis J; Ribrag V; Bouabdallah R; Morschhauser F; Navarro R; Le Gouill S; Haioun C; Houot R; Casasnovas O; Holte H; Lamy T; Broussais F; Payrard S; Hatteville L; Tilly H
    Br J Haematol; 2016 Jun; 173(5):722-30. PubMed ID: 27010483
    [TBL] [Abstract][Full Text] [Related]  

  • 92. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
    Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
    J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management.
    Ansell SM
    Am J Hematol; 2016 Jun; 91(4):434-42. PubMed ID: 27001163
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.
    Tessoulin B; Ceballos P; Chevallier P; Blaise D; Tournilhac O; Gauthier J; Maillard N; Tabrizi R; Choquet S; Carras S; Ifrah N; Guillerm G; Mohty M; Tilly H; Socie G; Cornillon J; Hermine O; Daguindau É; Bachy E; Girault S; Marchand T; Oberic L; Reman O; Leux C; Le Gouill S
    Bone Marrow Transplant; 2016 Sep; 51(9):1184-90. PubMed ID: 27111043
    [TBL] [Abstract][Full Text] [Related]  

  • 95. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.
    Glass J; Won M; Schultz CJ; Brat D; Bartlett NL; Suh JH; Werner-Wasik M; Fisher BJ; Liepman MK; Augspurger M; Bokstein F; Bovi JA; Solhjem MC; Mehta MP
    J Clin Oncol; 2016 May; 34(14):1620-5. PubMed ID: 27022122
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma.
    Cho H; Chang JH; Kim YR; Kim SJ; Chung H; Park H; Lee JY; Jang JE; Kim Y; Kim SH; Yang WI; Suh CO; Cheong JW; Min YH; Kim JS
    Br J Haematol; 2016 Aug; 174(3):444-53. PubMed ID: 27018207
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
    Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
    Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.
    Georgiou K; Chen L; Berglund M; Ren W; de Miranda NF; Lisboa S; Fangazio M; Zhu S; Hou Y; Wu K; Fang W; Wang X; Meng B; Zhang L; Zeng Y; Bhagat G; Nordenskjöld M; Sundström C; Enblad G; Dalla-Favera R; Zhang H; Teixeira MR; Pasqualucci L; Peng R; Pan-Hammarström Q
    Blood; 2016 Jun; 127(24):3026-34. PubMed ID: 27030389
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
    Hitz F; Zucca E; Pabst T; Fischer N; Cairoli A; Samaras P; Caspar CB; Mach N; Krasniqi F; Schmidt A; Rothermundt C; Enoiu M; Eckhardt K; Berardi Vilei S; Rondeau S; Mey U
    Br J Haematol; 2016 Jul; 174(2):255-63. PubMed ID: 27018242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.